{"id":"tapinarof","_fda":{"id":"4615ce09-cf4d-4410-91ff-db3caea7a802","set_id":"9309d20f-8cd4-4c96-93fa-7f730e83c7ab","openfda":{"nui":["N0000194018","N0000194019"],"unii":["84HW7D0V04"],"route":["TOPICAL"],"rxcui":["2602301","2602306"],"spl_id":["4615ce09-cf4d-4410-91ff-db3caea7a802"],"brand_name":["VTAMA"],"spl_set_id":["9309d20f-8cd4-4c96-93fa-7f730e83c7ab"],"package_ndc":["81672-5051-1"],"product_ndc":["81672-5051"],"generic_name":["TAPINAROF"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["TAPINAROF"],"pharm_class_epc":["Aryl Hydrocarbon Receptor Agonist [EPC]"],"pharm_class_moa":["Aryl Hydrocarbon Receptor Agonists [MoA]"],"manufacturer_name":["Organon LLC"],"application_number":["NDA215272"],"is_original_packager":[true]},"version":"4","pregnancy":["8.1 Pregnancy Risk Summary The available data on VTAMA cream use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, subcutaneous administration of tapinarof to pregnant rats and rabbits during the period of organogenesis resulted in no significant adverse effects at doses 264 and 16 times, respectively, the maximum recommended human dose (MRHD) ( see Data ). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of major birth defects, loss, and other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data In an embryofetal development study in rats, tapinarof was administered by subcutaneous injection to pregnant animals at doses of 1.2, 6.9 and 34 mg/kg/day during the period of organogenesis. Tapinarof was not associated with embryofetal lethality or fetal malformations. Tapinarof increased the incidence of skeletal variations (incomplete ossification of nasal bones) at the dose of 34 mg/kg/day (264 times the MRHD based on AUC comparisons). In an embryofetal development study in rabbits, tapinarof was administered by subcutaneous injection to pregnant animals twice daily at doses of 0.3, 1, and 3 mg/kg/day during the period of organogenesis. Maternal toxicity as evidenced by decreased maternal body weight gain and associated increased post-implantation loss (embryolethality) was observed at 3 mg/kg/day. In addition, fetal skeletal variations were observed at 3 mg/kg/day. Tapinarof was not associated with embryofetal lethality or fetal malformations at doses up to 1 mg/kg/day (16 times the MRHD based on AUC comparison) or fetal malformations at doses up to 3 mg/kg/day (30 times the MRHD based on AUC comparison). In a second embryofetal development study in rabbits, tapinarof was administered by continuous subcutaneous infusion to pregnant animals at doses of 1, 2 and 3 mg/kg/day during the period of organogenesis. Tapinarof was not associated with embryofetal lethality or fetal malformations at doses up to 3 mg/kg/day (20 times the MRHD based on AUC comparison). In a prenatal and postnatal development study, tapinarof was administered by subcutaneous injection to pregnant rats at doses of 1, 6 and 30 mg/kg/day beginning on gestation day 6 through lactation day 20. Maternal toxicity associated with decreases in body weight gain and food consumption was noted at 30 mg/kg/day (264 times the MRHD based on AUC comparisons). Tapinarof decreased fetal survival and viability that resulted in reduced litter sizes and decreased fetal weights at doses greater than or equal to 6 mg/kg/day (44 times the MRHD based on AUC comparisons). No tapinarof-related effects on fetal survival and viability were noted at a dose of 1 mg/kg/day (6 times the MRHD based on AUC comparisons). No tapinarof-related effects on postnatal development, neurobehavioral or reproductive performance of offspring were noted at doses up to 30 mg/kg/day (264 times the MRHD based on AUC comparison)."],"description":["11 DESCRIPTION VTAMA (tapinarof) cream contains tapinarof as the active ingredient. Tapinarof is an aryl hydrocarbon receptor agonist. Tapinarof is a white to pale brown powder. Chemically, tapinarof is 3, 5-dihydroxy-4-isopropyl- trans -stilbene, also known as (E)-2-isopropyl-5-styrylbenzene-1,3-diol, with the empirical formula C 17 H 18 O 2 , a molecular weight of 254.32, and the following structural formula. Each gram of VTAMA cream for topical use contains 10 mg of tapinarof in a white to off-white cream. VTAMA cream also contains the following inactive ingredients: benzoic acid, butylated hydroxytoluene, citric acid monohydrate, diethylene glycol monoethyl ether, edetate disodium, emulsifying wax, medium-chain triglycerides, polyoxyl 2 stearyl ether, polyoxyl 20 stearyl ether, polysorbate 80, propylene glycol, purified water, and sodium citrate dihydrate. figure1"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING VTAMA (tapinarof) cream, 1% is a white to off-white cream. Each gram of VTAMA cream contains 10 mg of tapinarof. It is supplied in the following size: 60 g laminated tubes: NDC 81672-5051-1 Storage and Handling: - Store at 20°C to 25°C (68°F to 77°F) excursions permitted between 15°C and 30°C (59°F and 86°F) [See USP Controlled Room Temperature]. - Do not freeze. - Protect from exposure to excessive heat."],"geriatric_use":["8.5 Geriatric Use Plaque Psoriasis Of the 683 subjects exposed to VTAMA cream in the PSOARING 1 or PSOARING 2 clinical trials, 99 (14.5%) were 65 years of age and older, including 8 (1.2%) subjects who were 75 years of age and older. No overall differences in efficacy, safety, or tolerability of VTAMA cream were observed between subjects 65 years of age and older and younger adult subjects. Atopic Dermatitis Of the 541 subjects exposed to VTAMA cream in the ADORING 1 or ADORING 2 clinical trials, 20 (3.7%) were 65 years of age and older, including 4 (0.7%) subjects who were 75 years of age and older. No overall differences in efficacy, safety, or tolerability were observed between subjects 65 years of age and older and younger adult subjects."],"pediatric_use":["8.4 Pediatric Use Plaque Psoriasis The safety and efficacy of VTAMA cream for the topical treatment of plaque psoriasis have not been established in pediatric patients. Atopic Dermatitis The safety and efficacy of VTAMA cream for the topical treatment of atopic dermatitis have been established in pediatric patients 2 years of age and older. Use of VTAMA cream for this indication is supported by evidence from two adequate and well-controlled trials (ADORING 1 and ADORING 2), which included 654 pediatric subjects 2 years of age and older (436 of whom received VTAMA cream) with moderate to severe atopic dermatitis. Adverse reactions occurring more frequently in pediatric subjects compared to adults were upper respiratory tract infection and ear infection [see Adverse Reactions (6.1) , Clinical Pharmacology (12.3) and Clinical Studies (14.2) ]. The safety and efficacy of VTAMA cream for the topical treatment of atopic dermatitis have not been established in pediatric patients younger than 2 years of age. Juvenile Animal Toxicity Data In a juvenile animal toxicity study, tapinarof was administered by subcutaneous injection to juvenile rats at doses of 1, 10 and 20 mg/kg/day from postnatal day (PND) 7 to 21 and at doses of 1.5, 15, and 30 mg/kg/day from PND 22 to 77. The dose escalation conducted at PND 22 was implemented to maintain consistent systemic exposure across the duration of the dosing period. Renal pelvic dilatation was observed at doses greater than or equal to 15 mg/kg/day (165 times the MRHD based on AUC comparisons). No adverse effects in juvenile animals were noted at 1.5 mg/kg/day (11 times the MRHD based on AUC comparisons)."],"effective_time":"20250528","clinical_studies":["14 CLINICAL STUDIES 14.1 Plaque Psoriasis Two multicenter, randomized, double-blind, vehicle-controlled trials were conducted to evaluate the safety and efficacy of VTAMA cream for the treatment of adults with plaque psoriasis (PSOARING 1 [NCT03956355] and PSOARING 2 [NCT03983980]). These trials were conducted in a total of 1025 subjects randomized 2:1 to VTAMA cream or vehicle cream applied once daily for 12 weeks to any lesion regardless of anatomic location. Baseline disease severity was graded using the 5-point Physician’s Global Assessment (PGA). The majority of subjects had “Moderate” disease (82%), while 10% had “Mild” disease, and 8% had “Severe” disease at baseline. The extent of disease involvement assessed by mean body surface area (BSA), excluding the scalp, palms, and soles, was 8% (range 3 to 20%). Subjects ranged in age from 18 to 75 years, with a median age of 51 years. Overall, 57% of the subjects were male and 85% were White. The primary efficacy endpoint in both studies was the proportion of subjects who achieved treatment success, defined as a PGA score of “Clear” (0) or “Almost Clear” (1) and at least a 2-grade improvement from baseline. Efficacy results from the two trials are summarized in Table 4. Table 4: Clinical Response at Week 12 in PSOARING 1 and PSOARING 2 in Adults with Plaque Psoriasis (Intent-to-Treat; Multiple Imputation) Clinical Response PSOARING 1 PSOARING 2 VTAMA cream N=340 Vehicle cream N=170 VTAMA cream N=343 Vehicle cream N=172 PGA Treatment Success Treatment success was defined as a PGA score of “Clear” or “Almost Clear” and at least a 2-grade improvement from baseline. 36% 6% 40% 6% Difference (95% CI) 29% (22%, 36%) 34% (27%, 41%) Following 12 weeks of treatment, 73 subjects randomized to VTAMA achieved complete disease clearance (PGA 0) and had VTAMA withdrawn. These subjects were followed for up to 40 additional weeks with a median time to first worsening (PGA ≥ 2 [“Mild”]) of 114 days (95% CI: 85, 142). 14.2 Atopic Dermatitis Two multicenter, randomized, double-blind, vehicle-controlled trials were conducted to evaluate the safety and efficacy of VTAMA cream for the treatment of adult and pediatric subjects 2 years of age and older with atopic dermatitis (ADORING 1 [NCT05014568] and ADORING 2 [NCT05032859]). These trials were conducted in a total of 813 subjects (80% of subjects were 2 to 17 years of age) randomized 2:1 to VTAMA cream or vehicle cream applied once daily for 8 weeks to any lesion regardless of anatomic location. Baseline disease severity was graded using the 5-point validated Investigator’s Global Assessment (vIGA-AD™). The majority of subjects had “Moderate” disease (87%), while 13% had “Severe” disease at baseline. The extent of disease involvement assessed by mean affected BSA, excluding the scalp, was 16.8% (range 5 to 44%). The mean baseline Eczema Area and Severity Index (EASI) score was 12.9 (range 4.4 to 36.0). The mean baseline Peak Pruritus Numeric Rating Scale (PP-NRS) score for subjects 12 years of age and older was 6.4 on a scale of 0-10. Subjects ranged in age from 2 to 81 years, with a median age of 11 years. Overall, 54% of the subjects were female, 51% were White, 31% were Black, and 12% were Asian. For ethnicity, 78% of subjects identified as non-Hispanic or Latino. The primary efficacy endpoint in both trials was the proportion of subjects who achieved treatment success, defined as a vIGA-AD score of “Clear” (0) or “Almost Clear” (1) and at least a 2-grade improvement from baseline. Efficacy was also assessed using a ≥ 4-point improvement in PP-NRS score in subjects 12 years of age and older. Efficacy results from the two trials are summarized in Table 5. Table 5: Clinical Response at Week 8 in ADORING 1 and ADORING 2 in Adult and Pediatric Subjects with Atopic Dermatitis (Intent-to-Treat; Multiple Imputation) ADORING 1 ADORING 2 VTAMA cream Vehicle cream VTAMA cream Vehicle cream Number of subjects randomized 270 137 271 135 vIGA-AD Treatment Success Based on number of subjects randomized. , Treatment success was defined as a vIGA-AD score of “Clear” or “Almost Clear” and at least a 2-grade improvement from baseline. Difference from Vehicle (95% CI) 45% 32% (23%, 40%) 14% 46% 29% (19%, 38%) 18% Number of subjects ≥12 years of age with baseline PP-NRS score ≥4 103 54 126 64 ≥ 4-point improvement in PP-NRS Based on number of subjects 12 years of age and older whose baseline PP-NRS score was ≥4. Difference from Vehicle (95% CI) 56% 22% (5%, 38%) 34% 53% 29% (15%, 43%) 24% Of the 431 subjects randomized to VTAMA who completed 8 weeks of treatment in ADORING 1 and ADORING 2 and elected to continue follow-up, 51 subjects achieved complete disease clearance (vIGA-AD = 0) and had VTAMA withdrawn. These subjects were followed for up to 48 additional weeks with a median time to first worsening (vIGA-AD ≥ 2 [“Mild”]) of 57 days (95% CI: 30, 79)."],"pharmacodynamics":["12.2 Pharmacodynamics Pharmacodynamics of VTAMA cream are unknown. Cardiac Electrophysiology At the approved recommended dosage, VTAMA cream does not prolong the QTc interval to any clinically relevant extent."],"pharmacokinetics":["12.3 Pharmacokinetics The plasma concentrations of tapinarof were higher in pediatric subjects 2 years of age and older with atopic dermatitis when compared to adult subjects with plaque psoriasis. Absorption Adults with Plaque Psoriasis No accumulation was observed with repeat topical application. Plasma concentration of tapinarof was below the quantifiable limits (BQL) of the assay (lower limit of quantification was 50 pg/mL) in 68% of the PK samples. On Day 1, mean ± SD values of C max and AUC 0-last were 0.90 ± 1.4 ng/mL and 4.1 ± 6.3 ng.h/mL, respectively, following a mean daily dose of 5.23 g applied to a mean body surface area (BSA) involvement of 27.2% (range 21 to 46%) in 21 subjects with moderate to severe plaque psoriasis. On Day 29, the mean ± SD C max and AUC 0-last were 0.12 ± 0.15 ng/mL and 0.61 ± 0.65 ng.h/mL, respectively. Pediatric Subjects with Atopic Dermatitis The PK of VTAMA cream were investigated in 36 pediatric subjects 2 years of age and older with moderate to severe atopic dermatitis and a mean ± SD BSA involvement of 43% ± 15% (range 26% to 90%). In this study, subjects applied approximately 3.2 g/day for 27 days. Plasma concentrations were BQL in 25% of PK samples on Day 1 and 76% of PK samples on Day 28. On Day 1, the mean ± SD C max and AUC 0-last were 2.4 ± 3.9 ng/mL and 4.7 ± 5.6 ng.h/mL, respectively in the overall pediatric population with atopic dermatitis. The mean ± SD C max and AUC 0-last on Day 1 in pediatric subjects with atopic dermatitis stratified by age is shown in Table 3. Table 3: Pharmacokinetic Parameters of Tapinarof by Age Group in Pediatric Subjects with Atopic Dermatitis PK Parameter (Mean ± SD) 2 – 6 Years 7 – 11 Years 12 – 17 Years C ꚍ : concentration at the end of 24 h dosing interval on Day 28. Day 1 C max (ng/mL) 3.8 ± 5.87 2.2 ± 2.5 1.3 ± 1.8 AUC 0-t (ng.h/mL) 5.5 ± 6.2 5.2 ± 5.9 3.3 ± 4.8 Day 28 C ꚍ (ng/mL) 0.046 ± 0.107 0.089 ± 0.130 0.125 ± 0.413 Distribution Human plasma protein binding of tapinarof is approximately 99% in vitro . Elimination Metabolism Tapinarof is metabolized in the liver by multiple pathways including oxidation, glucuronidation, and sulfation in vitro . Drug Interaction Studies In Vitro Studies Cytochrome P450 (CYP) Enzymes: Tapinarof is not an inhibitor of CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4/5. Tapinarof is not an inducer of CYP1A2, CYP2B6 or CYP3A4. Transporter Systems: Tapinarof is not an inhibitor of BCRP, MATE1, MATE-2K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, or P-gp. Tapinarof is not a substrate for BCRP, OATP1B1, OATP1B3, or P-gp."],"adverse_reactions":["6 ADVERSE REACTIONS In plaque psoriasis, the most common adverse reactions (incidence ≥ 1%) were folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza. ( 6.1 ) In atopic dermatitis, the most common adverse reactions (incidence ≥ 1%) were upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Organon LLC, a subsidiary of Organon & Co., at 1-844-674-3200 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Plaque Psoriasis Clinical Trials In two randomized, double-blind, multicenter, vehicle-controlled clinical trials (PSOARING 1 and PSOARING 2), 1025 adults with plaque psoriasis were treated with VTAMA cream or received vehicle cream once daily for up to 12 weeks. Subjects ranged in age from 18 to 75 years, with an overall median age of 51 years. The majority of subjects were White (85%) and male (57%); and 85% identified as non-Hispanic or Latino. Table 1 presents adverse reactions that occurred in at least 1% of subjects treated with VTAMA cream, and for which the rate exceeded the rate for vehicle. Table 1: Adverse Reactions Occurring in ≥1% of Adult Subjects with Plaque Psoriasis (and More Frequently than Vehicle) in the 12-week PSOARING 1 and PSOARING 2 Clinical Trials Adverse Reaction VTAMA cream N=683 n (%) Vehicle cream N=342 n (%) Folliculitis Folliculitis includes application site folliculitis and folliculitis 140 (20) 3 (1) Nasopharyngitis Nasopharyngitis includes nasopharyngitis, nasal congestion, pharyngitis, respiratory tract infection (RTI) viral, rhinorrhea, sinus congestion, upper RTI, and viral upper RTI 73 (11) 31 (9) Contact dermatitis Contact dermatitis includes dermatitis, contact dermatitis, hand dermatitis, and rash 45 (7) 2 (1) Headache Headache includes headache, migraine, and tension headache 26 (4) 5 (1) Pruritus Pruritus includes application site pruritus, pruritus, generalized pruritus, and genital pruritus 20 (3) 2 (1) Influenza Influenza includes influenza and influenza-like illness 14 (2) 2 (1) Two (0.3%) subjects using VTAMA cream developed urticaria. Adverse reactions leading to treatment discontinuation in >1% of subjects who received VTAMA cream were contact dermatitis (2.9%) and folliculitis (2.8%). In an open label safety trial (PSOARING 3), 763 subjects were treated for up to an additional 40 weeks after completing PSOARING 1 or PSOARING 2. In addition to the adverse reactions reported in the 12-week PSOARING 1 and PSOARING 2 clinical trials, the following adverse reactions were reported: urticaria (1.0%) and drug eruption (0.7%). Atopic Dermatitis Clinical Trials In two randomized, double-blind, multicenter, vehicle-controlled clinical trials (ADORING 1 and ADORING 2), 811 adult and pediatric subjects 2 years of age and older with atopic dermatitis were treated with VTAMA cream or received vehicle cream once daily for up to 8 weeks. Subjects ranged in age from 2 to 81 years, with an overall median age of 11 years. The majority (51%) of subjects were White, 31% were Black, 12% were Asian; 54% were female; and 78% of subjects identified as non-Hispanic or Latino. Table 2 presents adverse reactions that occurred in at least 1% of subjects treated with VTAMA cream, and for which the rate exceeded the rate for vehicle. Table 2: Adverse Reactions Occurring in ≥1% of Adult and Pediatric Subjects 2 Years and Older with Atopic Dermatitis (and More Frequently than Vehicle) in the 8 week ADORING 1 and ADORING 2 Clinical Trials Adverse Reaction VTAMA cream N=541 n (%) Vehicle cream N=270 n (%) Upper respiratory tract infection Upper respiratory tract infection includes upper respiratory tract infection, nasopharyngitis, nasal congestion, sinusitis, pharyngitis streptococcal, cough, oropharyngeal pain, pharyngitis, acute sinusitis, streptococcal infection, streptococcus test positive, viral upper respiratory tract infection, viral infection, rhinorrhea, sinus congestion 66 (12) 15 (6) Folliculitis Folliculitis includes folliculitis, application site folliculitis, keratosis pilaris, follicular eczema 51 (9) 3 (1) Lower respiratory tract infection Lower respiratory tract infection includes lower respiratory tract infection, COVID-19, influenza, bronchitis, pneumonia 25 (5) 6 (2) Headache 23 (4) 3 (1) Asthma Asthma includes asthma, wheezing 12 (2) 1 (0) Vomiting 10 (2) 2 (1) Ear infection Ear infection includes ear infection, otitis media, otitis externa, otitis media acute 10 (2) 1 (0) Pain in extremity Pain in extremity includes pain in extremity, arthralgia 9 (2) 1 (0) Abdominal pain Abdominal pain includes abdominal pain and abdominal pain upper 6 (1) 0 (0) Application site reactions were reported in 19 (3.5%) subjects treated with VTAMA cream and 9 (3.3%) subjects receiving vehicle. The adverse reactions observed in pediatric subjects 2 years of age and older were generally consistent with those observed in adults with atopic dermatitis. Adverse reactions occurring more frequently in pediatric subjects compared to adults were upper respiratory tract infection (16.3% in subjects ages 2-6 years of age and 11.2% in subjects ages 7-17 years of age vs. 9.5% in subjects 18 years and older) and ear infection (5.7% in subjects ages 2-6 years of age and 1.4% in subjects ages 7-11 years of age vs. 0% in subjects 12 years and older). In an open label safety trial (ADORING 3), 728 subjects (124 adult and 604 pediatric subjects 2 years of age and older) were treated for up to 48 weeks. This included 624 subjects completing either ADORING 1 or ADORING 2, 28 subjects completing the maximal usage trial, and 76 subjects treated only in ADORING 3. The safety profile with long term use was generally consistent with the safety profile observed at Week 8."],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"description_table":["
"],"mechanism_of_action":["12.1 Mechanism of Action Tapinarof is an aryl hydrocarbon receptor (AhR) agonist. The specific mechanisms by which VTAMA cream exerts its therapeutic actions are unknown."],"recent_major_changes":["Indications and Usage ( 1.2 ) 12/2024"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tapinarof is an aryl hydrocarbon receptor (AhR) agonist. The specific mechanisms by which VTAMA cream exerts its therapeutic actions are unknown. 12.2 Pharmacodynamics Pharmacodynamics of VTAMA cream are unknown. Cardiac Electrophysiology At the approved recommended dosage, VTAMA cream does not prolong the QTc interval to any clinically relevant extent. 12.3 Pharmacokinetics The plasma concentrations of tapinarof were higher in pediatric subjects 2 years of age and older with atopic dermatitis when compared to adult subjects with plaque psoriasis. Absorption Adults with Plaque Psoriasis No accumulation was observed with repeat topical application. Plasma concentration of tapinarof was below the quantifiable limits (BQL) of the assay (lower limit of quantification was 50 pg/mL) in 68% of the PK samples. On Day 1, mean ± SD values of C max and AUC 0-last were 0.90 ± 1.4 ng/mL and 4.1 ± 6.3 ng.h/mL, respectively, following a mean daily dose of 5.23 g applied to a mean body surface area (BSA) involvement of 27.2% (range 21 to 46%) in 21 subjects with moderate to severe plaque psoriasis. On Day 29, the mean ± SD C max and AUC 0-last were 0.12 ± 0.15 ng/mL and 0.61 ± 0.65 ng.h/mL, respectively. Pediatric Subjects with Atopic Dermatitis The PK of VTAMA cream were investigated in 36 pediatric subjects 2 years of age and older with moderate to severe atopic dermatitis and a mean ± SD BSA involvement of 43% ± 15% (range 26% to 90%). In this study, subjects applied approximately 3.2 g/day for 27 days. Plasma concentrations were BQL in 25% of PK samples on Day 1 and 76% of PK samples on Day 28. On Day 1, the mean ± SD C max and AUC 0-last were 2.4 ± 3.9 ng/mL and 4.7 ± 5.6 ng.h/mL, respectively in the overall pediatric population with atopic dermatitis. The mean ± SD C max and AUC 0-last on Day 1 in pediatric subjects with atopic dermatitis stratified by age is shown in Table 3. Table 3: Pharmacokinetic Parameters of Tapinarof by Age Group in Pediatric Subjects with Atopic Dermatitis PK Parameter (Mean ± SD) 2 – 6 Years 7 – 11 Years 12 – 17 Years C ꚍ : concentration at the end of 24 h dosing interval on Day 28. Day 1 C max (ng/mL) 3.8 ± 5.87 2.2 ± 2.5 1.3 ± 1.8 AUC 0-t (ng.h/mL) 5.5 ± 6.2 5.2 ± 5.9 3.3 ± 4.8 Day 28 C ꚍ (ng/mL) 0.046 ± 0.107 0.089 ± 0.130 0.125 ± 0.413 Distribution Human plasma protein binding of tapinarof is approximately 99% in vitro . Elimination Metabolism Tapinarof is metabolized in the liver by multiple pathways including oxidation, glucuronidation, and sulfation in vitro . Drug Interaction Studies In Vitro Studies Cytochrome P450 (CYP) Enzymes: Tapinarof is not an inhibitor of CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4/5. Tapinarof is not an inducer of CYP1A2, CYP2B6 or CYP3A4. Transporter Systems: Tapinarof is not an inhibitor of BCRP, MATE1, MATE-2K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, or P-gp. Tapinarof is not a substrate for BCRP, OATP1B1, OATP1B3, or P-gp."],"indications_and_usage":["1 INDICATIONS AND USAGE VTAMA cream, 1% is an aryl hydrocarbon receptor agonist indicated for: the topical treatment of plaque psoriasis in adults. ( 1.1 ) the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older. ( 1.2 ) 1.1 Plaque Psoriasis VTAMA ® cream is indicated for the topical treatment of plaque psoriasis in adults. 1.2 Atopic Dermatitis VTAMA cream is indicated for the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older."],"clinical_studies_table":["
Table 4: Clinical Response at Week 12 in PSOARING 1 and PSOARING 2 in Adults with Plaque Psoriasis (Intent-to-Treat; Multiple Imputation)
Clinical ResponsePSOARING 1PSOARING 2
VTAMA cream N=340Vehicle cream N=170VTAMA cream N=343Vehicle cream N=172
PGA Treatment Success Treatment success was defined as a PGA score of “Clear” or “Almost Clear” and at least a 2-grade improvement from baseline.36%6%40%6%
Difference (95% CI)29% (22%, 36%)34% (27%, 41%)
","
Table 5: Clinical Response at Week 8 in ADORING 1 and ADORING 2 in Adult and Pediatric Subjects with Atopic Dermatitis (Intent-to-Treat; Multiple Imputation)
ADORING 1ADORING 2
VTAMA creamVehicle creamVTAMA creamVehicle cream
Number of subjects randomized270137271135
vIGA-AD Treatment SuccessBased on number of subjects randomized.,Treatment success was defined as a vIGA-AD score of “Clear” or “Almost Clear” and at least a 2-grade improvement from baseline. Difference from Vehicle (95% CI)45% 32% (23%, 40%)14%46% 29% (19%, 38%)18%
Number of subjects ≥12 years of age with baseline PP-NRS score ≥41035412664
≥ 4-point improvement in PP-NRSBased on number of subjects 12 years of age and older whose baseline PP-NRS score was ≥4. Difference from Vehicle (95% CI)56% 22% (5%, 38%)34%53% 29% (15%, 43%)24%
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term carcinogenicity studies were conducted in mice (daily topical administration at doses of 0.5, 1.5 and 3% tapinarof cream) and in rats (subcutaneous administration at doses of 0.1, 0.3, and 1 mg/kg/day tapinarof). No drug-related neoplasms were noted in mice after 98 (females) to 102 (males) weeks of daily topical administration at doses up to 3% tapinarof cream (44 times the MRHD based on AUC comparisons). No drug-related neoplasms were noted in female rats after 83 weeks of daily subcutaneous administration at doses up to 1 mg/kg/day tapinarof (9 times the MRHD based on AUC comparisons). Tapinarof revealed no evidence of mutagenicity or clastogenicity in an Ames assay, an in vitro mammalian chromosomal aberration assay, an in vitro mouse lymphoma assay and two in vivo micronucleus-assays in mice and rats. Tapinarof did not impair female fertility at subcutaneous doses up to 30 mg/kg/day (264 times the MRHD based on AUC comparisons)."],"pharmacokinetics_table":["
Table 3: Pharmacokinetic Parameters of Tapinarof by Age Group in Pediatric Subjects with Atopic Dermatitis
PK Parameter (Mean ± SD)2 – 6 Years7 – 11 Years12 – 17 Years
Cꚍ: concentration at the end of 24 h dosing interval on Day 28.
Day 1
Cmax (ng/mL)3.8 ± 5.872.2 ± 2.51.3 ± 1.8
AUC0-t (ng.h/mL)5.5 ± 6.25.2 ± 5.93.3 ± 4.8
Day 28
Cꚍ (ng/mL)0.046 ± 0.1070.089 ± 0.1300.125 ± 0.413
"],"adverse_reactions_table":["
Table 1: Adverse Reactions Occurring in ≥1% of Adult Subjects with Plaque Psoriasis (and More Frequently than Vehicle) in the 12-week PSOARING 1 and PSOARING 2 Clinical Trials
Adverse ReactionVTAMA cream N=683 n (%)Vehicle cream N=342 n (%)
FolliculitisFolliculitis includes application site folliculitis and folliculitis140 (20)3 (1)
NasopharyngitisNasopharyngitis includes nasopharyngitis, nasal congestion, pharyngitis, respiratory tract infection (RTI) viral, rhinorrhea, sinus congestion, upper RTI, and viral upper RTI73 (11)31 (9)
Contact dermatitisContact dermatitis includes dermatitis, contact dermatitis, hand dermatitis, and rash45 (7)2 (1)
HeadacheHeadache includes headache, migraine, and tension headache26 (4)5 (1)
PruritusPruritus includes application site pruritus, pruritus, generalized pruritus, and genital pruritus20 (3)2 (1)
InfluenzaInfluenza includes influenza and influenza-like illness14 (2)2 (1)
","
Table 2: Adverse Reactions Occurring in ≥1% of Adult and Pediatric Subjects 2 Years and Older with Atopic Dermatitis (and More Frequently than Vehicle) in the 8 week ADORING 1 and ADORING 2 Clinical Trials
Adverse ReactionVTAMA cream N=541 n (%)Vehicle cream N=270 n (%)
Upper respiratory tract infectionUpper respiratory tract infection includes upper respiratory tract infection, nasopharyngitis, nasal congestion, sinusitis, pharyngitis streptococcal, cough, oropharyngeal pain, pharyngitis, acute sinusitis, streptococcal infection, streptococcus test positive, viral upper respiratory tract infection, viral infection, rhinorrhea, sinus congestion66 (12)15 (6)
FolliculitisFolliculitis includes folliculitis, application site folliculitis, keratosis pilaris, follicular eczema51 (9)3 (1)
Lower respiratory tract infectionLower respiratory tract infection includes lower respiratory tract infection, COVID-19, influenza, bronchitis, pneumonia25 (5)6 (2)
Headache23 (4)3 (1)
AsthmaAsthma includes asthma, wheezing12 (2)1 (0)
Vomiting10 (2)2 (1)
Ear infectionEar infection includes ear infection, otitis media, otitis externa, otitis media acute10 (2)1 (0)
Pain in extremityPain in extremity includes pain in extremity, arthralgia9 (2)1 (0)
Abdominal painAbdominal pain includes abdominal pain and abdominal pain upper6 (1)0 (0)
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Patient Information ). Administration Instructions [see Dosage and Administration (2) ] Instruct patients to apply VTAMA cream once daily to affected skin lesions only and avoid unaffected areas of skin. Advise patients to wash hands after application unless VTAMA cream is for treatment of the hands. Advise patients that VTAMA cream is for external use only. Dist. by: Organon LLC, a subsidiary of ORGANON & Co., Jersey City, NJ 07302, USA For patent information: www.organon.com/our-solutions/patent/ vIGA-AD is the trademark of Eli Lilly and Co. © 2025 Organon group of companies. All rights reserved. uspi-og0505-cr-2505r000"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Apply a thin layer of VTAMA cream to affected areas once daily. Wash hands after application, unless VTAMA cream is for treatment of the hands. VTAMA cream is not for oral, ophthalmic, or intravaginal use. Apply a thin layer of VTAMA cream to affected areas once daily. ( 2 ) VTAMA cream is not for oral, ophthalmic, or intravaginal use. ( 2 )"],"spl_product_data_elements":["VTAMA tapinarof BENZOIC ACID BUTYLATED HYDROXYTOLUENE CITRIC ACID MONOHYDRATE DIETHYLENE GLYCOL MONOETHYL ETHER EDETATE DISODIUM MEDIUM-CHAIN TRIGLYCERIDES POLAWAX POLYSORBATE POLYSORBATE 80 PROPYLENE GLYCOL STEARETH-2 STEARETH-20 TRISODIUM CITRATE DIHYDRATE WATER TAPINAROF TAPINAROF"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Cream, 1% Each gram of VTAMA cream contains 10 mg of tapinarof in a white to off-white cream. Cream, 1% ( 3 ) Each gram of VTAMA cream contains 10 mg of tapinarof. ( 3 )"],"recent_major_changes_table":["
Indications and Usage (1.2)12/2024
"],"spl_patient_package_insert":["PATIENT INFORMATION VTAMA ® (Vee-TAM-uh) (tapinarof) cream, for topical use This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 5/2025 Important information: VTAMA cream is for use on the skin (topical use) only. Do not use VTAMA cream in your eyes, mouth, or vagina. What is VTAMA cream? VTAMA cream is a prescription medicine used on the skin (topical) to treat: plaque psoriasis in adults. atopic dermatitis in adults and children 2 years of age and older. It is not known if VTAMA cream is safe and effective for the topical treatment of plaque psoriasis in children. It is not known if VTAMA cream is safe and effective for the topical treatment of atopic dermatitis in children under 2 years of age. Before using VTAMA cream, tell your healthcare provider about all of your medical conditions, including if you: are pregnant or plan to become pregnant. It is not known if VTAMA cream will harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if VTAMA cream passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with VTAMA cream. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. How should I use VTAMA cream? Use VTAMA cream exactly as your healthcare provider tells you to use it. Apply a thin layer of VTAMA cream only to the affected skin areas 1 time a day. Avoid applying VTAMA cream to unaffected areas of your skin. Wash your hands after applying VTAMA cream unless you are using it to treat your hands. If someone else applies VTAMA cream for you, they should wash their hands after application. What are the possible side effects of VTAMA cream? The most common side effects of VTAMA cream in people treated for plaque psoriasis include : red raised bumps around the hair pores (folliculitis) pain or swelling in the nose and throat (nasopharyngitis) skin rash or irritation including itching and redness, peeling, burning, or stinging headache flu The most common side effects of VTAMA cream in people treated for atopic dermatitis include : upper and lower respiratory tract infections red raised bumps around the hair pores (folliculitis) headache asthma vomiting ear infection pain in extremity stomach-area (abdominal) pain VTAMA cream can also cause skin reactions at the treatment site. Tell your healthcare provider if you have itching, irritation, pain, redness, burning or changes in skin color at the treatment site. These are not all the possible side effects of VTAMA cream. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store VTAMA cream? Store VTAMA cream at room temperature between 68°F to 77°F (20°C to 25°C). Do not freeze VTAMA cream. Protect VTAMA cream from exposure to excessive heat. Keep VTAMA cream and all medicines out of the reach of children. General information about the safe and effective use of VTAMA cream. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VTAMA cream for a condition for which it was not prescribed. Do not give VTAMA cream to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about VTAMA cream that is written for health professionals. What are the ingredients in VTAMA cream? Active ingredient: tapinarof Inactive ingredients: benzoic acid, butylated hydroxytoluene, citric acid monohydrate, diethylene glycol monoethyl ether, edetate disodium, emulsifying wax, medium-chain triglycerides, polyoxyl 2 stearyl ether, polyoxyl 20 stearyl ether, polysorbate 80, propylene glycol, purified water, and sodium citrate dihydrate. Dist. by: Organon LLC, a subsidiary of ORGANON & Co., Jersey City, NJ 07302, USA For patent information: www.organon.com/our-solutions/patent/ © 2025 Organon group of companies. All rights reserved. usppi-og0505-cr-2505r000 For more information, go to www.VTAMA.com or call 1-844-674-3200."],"clinical_pharmacology_table":["
Table 3: Pharmacokinetic Parameters of Tapinarof by Age Group in Pediatric Subjects with Atopic Dermatitis
PK Parameter (Mean ± SD)2 – 6 Years7 – 11 Years12 – 17 Years
Cꚍ: concentration at the end of 24 h dosing interval on Day 28.
Day 1
Cmax (ng/mL)3.8 ± 5.872.2 ± 2.51.3 ± 1.8
AUC0-t (ng.h/mL)5.5 ± 6.25.2 ± 5.93.3 ± 4.8
Day 28
Cꚍ (ng/mL)0.046 ± 0.1070.089 ± 0.1300.125 ± 0.413
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary The available data on VTAMA cream use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, subcutaneous administration of tapinarof to pregnant rats and rabbits during the period of organogenesis resulted in no significant adverse effects at doses 264 and 16 times, respectively, the maximum recommended human dose (MRHD) ( see Data ). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of major birth defects, loss, and other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data In an embryofetal development study in rats, tapinarof was administered by subcutaneous injection to pregnant animals at doses of 1.2, 6.9 and 34 mg/kg/day during the period of organogenesis. Tapinarof was not associated with embryofetal lethality or fetal malformations. Tapinarof increased the incidence of skeletal variations (incomplete ossification of nasal bones) at the dose of 34 mg/kg/day (264 times the MRHD based on AUC comparisons). In an embryofetal development study in rabbits, tapinarof was administered by subcutaneous injection to pregnant animals twice daily at doses of 0.3, 1, and 3 mg/kg/day during the period of organogenesis. Maternal toxicity as evidenced by decreased maternal body weight gain and associated increased post-implantation loss (embryolethality) was observed at 3 mg/kg/day. In addition, fetal skeletal variations were observed at 3 mg/kg/day. Tapinarof was not associated with embryofetal lethality or fetal malformations at doses up to 1 mg/kg/day (16 times the MRHD based on AUC comparison) or fetal malformations at doses up to 3 mg/kg/day (30 times the MRHD based on AUC comparison). In a second embryofetal development study in rabbits, tapinarof was administered by continuous subcutaneous infusion to pregnant animals at doses of 1, 2 and 3 mg/kg/day during the period of organogenesis. Tapinarof was not associated with embryofetal lethality or fetal malformations at doses up to 3 mg/kg/day (20 times the MRHD based on AUC comparison). In a prenatal and postnatal development study, tapinarof was administered by subcutaneous injection to pregnant rats at doses of 1, 6 and 30 mg/kg/day beginning on gestation day 6 through lactation day 20. Maternal toxicity associated with decreases in body weight gain and food consumption was noted at 30 mg/kg/day (264 times the MRHD based on AUC comparisons). Tapinarof decreased fetal survival and viability that resulted in reduced litter sizes and decreased fetal weights at doses greater than or equal to 6 mg/kg/day (44 times the MRHD based on AUC comparisons). No tapinarof-related effects on fetal survival and viability were noted at a dose of 1 mg/kg/day (6 times the MRHD based on AUC comparisons). No tapinarof-related effects on postnatal development, neurobehavioral or reproductive performance of offspring were noted at doses up to 30 mg/kg/day (264 times the MRHD based on AUC comparison). 8.2 Lactation Risk Summary No data are available regarding the presence of tapinarof in human milk or the effects of tapinarof on the breastfed infant, or on milk production. Tapinarof was detected in rat offspring following subcutaneous administration to pregnant female rats which suggests that tapinarof was transferred into the milk of lactating rats (see Data ) . When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VTAMA cream and any potential adverse effects on the breastfed infant from VTAMA cream or from the underlying maternal condition. Data In a prenatal and postnatal development study, tapinarof was administered by subcutaneous injection to pregnant rats at doses of 1, 6, and 30 mg/kg/day from gestation day 6 through lactation day 20. Tapinarof was quantifiable in offspring plasma samples on postnatal day 10 at doses of 6 and 30 mg/kg/day, suggesting that tapinarof is present in animal milk. 8.4 Pediatric Use Plaque Psoriasis The safety and efficacy of VTAMA cream for the topical treatment of plaque psoriasis have not been established in pediatric patients. Atopic Dermatitis The safety and efficacy of VTAMA cream for the topical treatment of atopic dermatitis have been established in pediatric patients 2 years of age and older. Use of VTAMA cream for this indication is supported by evidence from two adequate and well-controlled trials (ADORING 1 and ADORING 2), which included 654 pediatric subjects 2 years of age and older (436 of whom received VTAMA cream) with moderate to severe atopic dermatitis. Adverse reactions occurring more frequently in pediatric subjects compared to adults were upper respiratory tract infection and ear infection [see Adverse Reactions (6.1) , Clinical Pharmacology (12.3) and Clinical Studies (14.2) ]. The safety and efficacy of VTAMA cream for the topical treatment of atopic dermatitis have not been established in pediatric patients younger than 2 years of age. Juvenile Animal Toxicity Data In a juvenile animal toxicity study, tapinarof was administered by subcutaneous injection to juvenile rats at doses of 1, 10 and 20 mg/kg/day from postnatal day (PND) 7 to 21 and at doses of 1.5, 15, and 30 mg/kg/day from PND 22 to 77. The dose escalation conducted at PND 22 was implemented to maintain consistent systemic exposure across the duration of the dosing period. Renal pelvic dilatation was observed at doses greater than or equal to 15 mg/kg/day (165 times the MRHD based on AUC comparisons). No adverse effects in juvenile animals were noted at 1.5 mg/kg/day (11 times the MRHD based on AUC comparisons). 8.5 Geriatric Use Plaque Psoriasis Of the 683 subjects exposed to VTAMA cream in the PSOARING 1 or PSOARING 2 clinical trials, 99 (14.5%) were 65 years of age and older, including 8 (1.2%) subjects who were 75 years of age and older. No overall differences in efficacy, safety, or tolerability of VTAMA cream were observed between subjects 65 years of age and older and younger adult subjects. Atopic Dermatitis Of the 541 subjects exposed to VTAMA cream in the ADORING 1 or ADORING 2 clinical trials, 20 (3.7%) were 65 years of age and older, including 4 (0.7%) subjects who were 75 years of age and older. No overall differences in efficacy, safety, or tolerability were observed between subjects 65 years of age and older and younger adult subjects."],"spl_patient_package_insert_table":["
PATIENT INFORMATION VTAMA® (Vee-TAM-uh) (tapinarof) cream, for topical use
This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 5/2025
Important information: VTAMA cream is for use on the skin (topical use) only. Do not use VTAMA cream in your eyes, mouth, or vagina.
What is VTAMA cream? VTAMA cream is a prescription medicine used on the skin (topical) to treat: plaque psoriasis in adults.atopic dermatitis in adults and children 2 years of age and older. It is not known if VTAMA cream is safe and effective for the topical treatment of plaque psoriasis in children. It is not known if VTAMA cream is safe and effective for the topical treatment of atopic dermatitis in children under 2 years of age.
Before using VTAMA cream, tell your healthcare provider about all of your medical conditions, including if you:are pregnant or plan to become pregnant. It is not known if VTAMA cream will harm your unborn baby.are breastfeeding or plan to breastfeed. It is not known if VTAMA cream passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with VTAMA cream.Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How should I use VTAMA cream?Use VTAMA cream exactly as your healthcare provider tells you to use it.Apply a thin layer of VTAMA cream only to the affected skin areas 1 time a day. Avoid applying VTAMA cream to unaffected areas of your skin.Wash your hands after applying VTAMA cream unless you are using it to treat your hands.If someone else applies VTAMA cream for you, they should wash their hands after application.
What are the possible side effects of VTAMA cream? The most common side effects of VTAMA cream in people treated for plaque psoriasis include:
red raised bumps around the hair pores (folliculitis)pain or swelling in the nose and throat (nasopharyngitis)skin rash or irritation including itching and redness, peeling, burning, or stingingheadacheflu
The most common side effects of VTAMA cream in people treated for atopic dermatitis include:
upper and lower respiratory tract infectionsred raised bumps around the hair pores (folliculitis)headacheasthmavomitingear infectionpain in extremitystomach-area (abdominal) pain
VTAMA cream can also cause skin reactions at the treatment site. Tell your healthcare provider if you have itching, irritation, pain, redness, burning or changes in skin color at the treatment site. These are not all the possible side effects of VTAMA cream. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store VTAMA cream?Store VTAMA cream at room temperature between 68°F to 77°F (20°C to 25°C).Do not freeze VTAMA cream.Protect VTAMA cream from exposure to excessive heat.Keep VTAMA cream and all medicines out of the reach of children.
General information about the safe and effective use of VTAMA cream. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VTAMA cream for a condition for which it was not prescribed. Do not give VTAMA cream to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about VTAMA cream that is written for health professionals.
What are the ingredients in VTAMA cream? Active ingredient: tapinarof Inactive ingredients: benzoic acid, butylated hydroxytoluene, citric acid monohydrate, diethylene glycol monoethyl ether, edetate disodium, emulsifying wax, medium-chain triglycerides, polyoxyl 2 stearyl ether, polyoxyl 20 stearyl ether, polysorbate 80, propylene glycol, purified water, and sodium citrate dihydrate. Dist. by: Organon LLC, a subsidiary of ORGANON & Co., Jersey City, NJ 07302, USA For patent information: www.organon.com/our-solutions/patent/ © 2025 Organon group of companies. All rights reserved. usppi-og0505-cr-2505r000 For more information, go to www.VTAMA.com or call 1-844-674-3200.
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL NDC 81672-5051-1 Rx only VTAMA ® (tapinarof) cream 1% For topical use only. 60g PRINCIPAL DISPLAY PANEL - 60g Carton","PRINCIPAL DISPLAY PANEL NDC 81672-5051-1 Rx only VTAMA ® (tapinarof) cream 1% For topical use only. 60g PRINCIPAL DISPLAY PANEL -"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term carcinogenicity studies were conducted in mice (daily topical administration at doses of 0.5, 1.5 and 3% tapinarof cream) and in rats (subcutaneous administration at doses of 0.1, 0.3, and 1 mg/kg/day tapinarof). No drug-related neoplasms were noted in mice after 98 (females) to 102 (males) weeks of daily topical administration at doses up to 3% tapinarof cream (44 times the MRHD based on AUC comparisons). No drug-related neoplasms were noted in female rats after 83 weeks of daily subcutaneous administration at doses up to 1 mg/kg/day tapinarof (9 times the MRHD based on AUC comparisons). Tapinarof revealed no evidence of mutagenicity or clastogenicity in an Ames assay, an in vitro mammalian chromosomal aberration assay, an in vitro mouse lymphoma assay and two in vivo micronucleus-assays in mice and rats. Tapinarof did not impair female fertility at subcutaneous doses up to 30 mg/kg/day (264 times the MRHD based on AUC comparisons)."]},"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"FOLLICULITIS","source":"FDA FAERS","actionTaken":"281 reports"},{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"188 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"157 reports"},{"date":"","signal":"DERMATITIS CONTACT","source":"FDA FAERS","actionTaken":"124 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"118 reports"},{"date":"","signal":"ERYTHEMA","source":"FDA FAERS","actionTaken":"102 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"99 reports"},{"date":"","signal":"SKIN BURNING SENSATION","source":"FDA FAERS","actionTaken":"81 reports"},{"date":"","signal":"PSORIASIS","source":"FDA FAERS","actionTaken":"64 reports"},{"date":"","signal":"APPLICATION SITE ERYTHEMA","source":"FDA FAERS","actionTaken":"56 reports"}],"commonSideEffects":[{"effect":"folliculitis","drugRate":"20%","_validated":true,"placeboRate":"1%"},{"effect":"nasopharyngitis","drugRate":"11%","_validated":true,"placeboRate":"9%"},{"effect":"contact dermatitis","drugRate":"7%","_validated":true,"placeboRate":"1%"},{"effect":"headache","drugRate":"4%","_validated":true,"placeboRate":"1%"},{"effect":"pruritus","drugRate":"3%","_validated":true,"placeboRate":"1%"},{"effect":"influenza","drugRate":"2%","_validated":true,"placeboRate":"1%"},{"effect":"upper respiratory tract infection","drugRate":"12%","_validated":true,"placeboRate":"6%"},{"effect":"folliculitis","drugRate":"9%","_validated":true,"placeboRate":"1%"},{"effect":"lower respiratory tract infection","drugRate":"5%","_validated":true,"placeboRate":"2%"},{"effect":"headache","drugRate":"4%","_validated":true,"placeboRate":"1%"},{"effect":"asthma","drugRate":"2%","_validated":true,"placeboRate":"0%"},{"effect":"vomiting","drugRate":"2%","_validated":true,"placeboRate":"1%"},{"effect":"ear infection","drugRate":"2%","_validated":true,"placeboRate":"0%"},{"effect":"pain in extremity","drugRate":"2%","_validated":true,"placeboRate":"1%"},{"effect":"abdominal pain","drugRate":"","placeboRate":""}],"discontinuationRates":[{"trial":"Plaque Psoriasis Clinical Trials","drugArm":"2.9%","placeboArm":"","commonReason":"contact dermatitis"},{"trial":"Plaque Psoriasis Clinical Trials","drugArm":"2.8%","placeboArm":"","commonReason":"folliculitis"}],"seriousAdverseEvents":[{"event":"urticaria","detail":"Two (0.3%) subjects using VTAMA cream developed urticaria.","severity":"serious","incidence":"0.3%"},{"event":"urticaria","detail":"In an open label safety trial (PSOARING 3), 763 subjects were treated for up to an additional 40 weeks after completing PSOARING 1 or PSOARING 2. In addition to the adverse reactions reported in the 12-week PSOARING 1 and PSOARING 2 clinical trials, the following adverse reactions were reported: urticaria (1.0%) and drug eruption (0.7%).","severity":"serious","incidence":"1.0%"},{"event":"drug eruption","detail":"In an open label safety trial (PSOARING 3), 763 subjects were treated for up to an additional 40 weeks after completing PSOARING 1 or PSOARING 2. In addition to the adverse reactions reported in the 12-week PSOARING 1 and PSOARING 2 clinical trials, the following adverse reactions were reported: urticaria (1.0%) and drug eruption (0.7%).","severity":"serious","incidence":"0.7%"}]},"_chembl":{"chemblId":"CHEMBL259571","moleculeType":"Small molecule","molecularWeight":"254.33"},"patents":[{"applNo":"N215272","source":"FDA Orange Book","status":"Active","expires":"Nov 13, 2039","territory":"US","drugProduct":false,"patentNumber":"11590088","drugSubstance":false},{"applNo":"N215272","source":"FDA Orange Book","status":"Active","expires":"May 19, 2036","territory":"US","drugProduct":false,"patentNumber":"10426743","drugSubstance":false},{"applNo":"N215272","source":"FDA Orange Book","status":"Active","expires":"May 19, 2036","territory":"US","drugProduct":false,"patentNumber":"11612573","drugSubstance":false},{"applNo":"N215272","source":"FDA Orange Book","status":"Active","expires":"Nov 13, 2039","territory":"US","drugProduct":false,"patentNumber":"11497718","drugSubstance":false},{"applNo":"N215272","source":"FDA Orange Book","status":"Active","expires":"Nov 13, 2039","territory":"US","drugProduct":false,"patentNumber":"11938099","drugSubstance":false},{"applNo":"N215272","source":"FDA Orange Book","status":"Active","expires":"Nov 13, 2038","territory":"US","drugProduct":false,"patentNumber":"10647649","drugSubstance":true},{"applNo":"N215272","source":"FDA Orange Book","status":"Active","expires":"May 19, 2036","territory":"US","drugProduct":true,"patentNumber":"11617724","drugSubstance":false},{"applNo":"N215272","source":"FDA Orange Book","status":"Active","expires":"Nov 13, 2038","territory":"US","drugProduct":true,"patentNumber":"11597692","drugSubstance":true},{"applNo":"N215272","source":"FDA Orange Book","status":"Active","expires":"May 19, 2036","territory":"US","drugProduct":true,"patentNumber":"10195160","drugSubstance":false},{"applNo":"N215272","source":"FDA Orange Book","status":"Active","expires":"May 19, 2036","territory":"US","drugProduct":true,"patentNumber":"11622945","drugSubstance":false},{"applNo":"N215272","source":"FDA Orange Book","status":"Active","expires":"May 19, 2036","territory":"US","drugProduct":true,"patentNumber":"11458108","drugSubstance":false}],"_fixedAt":"2026-03-30T12:22:41.464585","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TAPINAROF","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:54:13.945961+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:54:13.945880+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:54:20.382539+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:54:12.069358+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TAPINAROF","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:54:21.016060+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:54:11.161698+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:54:11.161798+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:54:11.161817+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:54:22.501588+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Tapinarof is an aryl hydrocarbon receptor (AhR) agonist. The specific mechanisms by which VTAMA cream exerts its therapeutic actions are unknown.","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:54:31.536298+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Aryl hydrocarbon receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:54:21.553165+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL259571/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:54:21.462895+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS In plaque psoriasis, the most common adverse reactions (incidence ≥ 1%) were folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza. ( 6.1 ) In atopic dermatitis, the most common adverse reactions (incidence ≥ 1%) were upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Organon LL","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:55:14.101726+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA215272","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:54:11.161824+00:00"}},"_dailymed":{"setId":"9309d20f-8cd4-4c96-93fa-7f730e83c7ab","title":"VTAMA (TAPINAROF) CREAM [ORGANON LLC]"},"mechanism":{"target":"aryl hydrocarbon receptor (AhR)","modality":"Small Molecule","drugClass":"Aryl Hydrocarbon Receptor Agonist [EPC]","explanation":"Tapinarof is known to activate the aryl hydrocarbon receptor (AhR). However, the specific ways in which this activation leads to the therapeutic benefits of VTAMA cream are not fully understood.","oneSentence":"Tapinarof activates the aryl hydrocarbon receptor (AhR), but the exact mechanisms of its therapeutic effects are unknown.","technicalDetail":"Tapinarof is an aryl hydrocarbon receptor (AhR) agonist. The precise mechanisms by which it exerts its therapeutic actions are currently unknown."},"_scrapedAt":"2026-03-27T23:38:22.644Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:55:16.637510+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_fixedFields":["sideEffects","patents(11)","modality→Small Molecule"],"trialDetails":[{"nctId":"NCT07265479","phase":"PHASE3","title":"A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis","status":"RECRUITING","sponsor":"Organon and Co","startDate":"2025-12-29","conditions":"Atopic Dermatitis","enrollment":180},{"nctId":"NCT06561321","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma","status":"RECRUITING","sponsor":"Indiana University","startDate":"2024-10-30","conditions":"Palmoplantar Keratoderma","enrollment":6},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT05172726","phase":"PHASE3","title":"Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Organon and Co","startDate":"2021-12-02","conditions":"Plaque Psoriasis","enrollment":58},{"nctId":"NCT05981118","phase":"PHASE2, PHASE3","title":"Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)","status":"ENROLLING_BY_INVITATION","sponsor":"Wake Forest University Health Sciences","startDate":"2024-07-15","conditions":"ICD10 Code L40.9 for Psoriasis","enrollment":40},{"nctId":"NCT06742957","phase":"PHASE3","title":"Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2024-12-17","conditions":"Plaque Type Psorisis","enrollment":560},{"nctId":"NCT05186805","phase":"PHASE2","title":"Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2021-11-15","conditions":"Atopic Dermatitis","enrollment":36},{"nctId":"NCT05014568","phase":"PHASE3","title":"Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2021-09-01","conditions":"Atopic Dermatitis","enrollment":407},{"nctId":"NCT05032859","phase":"PHASE3","title":"Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2021-09-23","conditions":"Atopic Dermatitis","enrollment":406},{"nctId":"NCT05142774","phase":"PHASE3","title":"Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2021-10-28","conditions":"Atopic Dermatitis","enrollment":728},{"nctId":"NCT04053387","phase":"PHASE3","title":"Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2019-08-13","conditions":"Plaque Psoriasis","enrollment":763},{"nctId":"NCT04042103","phase":"PHASE2","title":"Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2019-07-23","conditions":"Plaque Psoriasis","enrollment":21},{"nctId":"NCT05789576","phase":"PHASE4","title":"A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2023-03-13","conditions":"Psoriasis","enrollment":31},{"nctId":"NCT03956355","phase":"PHASE3","title":"Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2019-05-21","conditions":"Plaque Psoriasis","enrollment":510},{"nctId":"NCT05680740","phase":"PHASE4","title":"A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2022-12-27","conditions":"Psoriasis","enrollment":34},{"nctId":"NCT03983980","phase":"PHASE3","title":"Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2019-06-06","conditions":"Plaque Psoriasis","enrollment":515},{"nctId":"NCT06661213","phase":"EARLY_PHASE1","title":"Tapinarof for Cutaneous Lupus Erythematosus","status":"ENROLLING_BY_INVITATION","sponsor":"Northwestern University","startDate":"2025-04-03","conditions":"Cutaneous Lupus Erythematosus","enrollment":10},{"nctId":"NCT06103695","phase":"PHASE4","title":"Vtama in Psoriasis Patients Being Treated With Biologics.","status":"COMPLETED","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2023-02-27","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT05064748","phase":"PHASE4","title":"Phase IV Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Psoriasis in Adults","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2021-06-01","conditions":"Psoriasis","enrollment":2000},{"nctId":"NCT03202004","phase":"PHASE3","title":"GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2018-01-22","conditions":"Psoriasis","enrollment":""},{"nctId":"NCT03201978","phase":"PHASE1","title":"A Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of GSK2894512 in Healthy Adult Subjects","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2017-12-14","conditions":"Psoriasis","enrollment":""},{"nctId":"NCT02564055","phase":"PHASE2","title":"A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-12-01","conditions":"Dermatitis, Atopic","enrollment":247},{"nctId":"NCT02564042","phase":"PHASE2","title":"A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-11-23","conditions":"Psoriasis","enrollment":227},{"nctId":"NCT01098721","phase":"PHASE2","title":"A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks","status":"COMPLETED","sponsor":"Welichem Biotech Inc.","startDate":"2010-01","conditions":"Psoriasis","enrollment":61},{"nctId":"NCT01098734","phase":"PHASE2","title":"Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream","status":"COMPLETED","sponsor":"Welichem Biotech Inc.","startDate":"2009-11","conditions":"Dermatitis, Atopic","enrollment":148},{"nctId":"NCT00837551","phase":"PHASE1, PHASE2","title":"Phase IIa Study of WBI-1001 Cream for Atopic Dermatitis","status":"COMPLETED","sponsor":"Welichem Biotech Inc.","startDate":"2008-03","conditions":"Dermatitis, Atopic","enrollment":36}],"_emaApprovals":[],"_faersSignals":[{"count":235,"reaction":"FOLLICULITIS"},{"count":121,"reaction":"PRURITUS"},{"count":97,"reaction":"DERMATITIS CONTACT"},{"count":95,"reaction":"HEADACHE"},{"count":81,"reaction":"RASH"},{"count":64,"reaction":"SKIN BURNING SENSATION"},{"count":61,"reaction":"ERYTHEMA"},{"count":45,"reaction":"DRUG INEFFECTIVE"},{"count":40,"reaction":"APPLICATION SITE ERYTHEMA"},{"count":40,"reaction":"PAIN OF SKIN"}],"administration":{"route":"Topical"},"_patentsChecked":true,"crossReferences":{"chemblId":"CHEMBL259571"},"_approvalHistory":[],"publicationCount":191,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"TAPINAROF","genericName":"TAPINAROF","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"2022","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-12-12T00:00:00.000Z","mah":"ORGANON LLC","brand_name_local":null,"application_number":"NDA215272"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":3},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:55:16.637510+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}